Disease · MONDO_0005246
osteomyelitis
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. osteomyelitis. Diseases, record MONDO_0005246. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005246
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
Osteomyelitis of ankle and/or foot (disorder), Osteomyelitis of forearm (disorder), Osteomyelitis of hand (disorder), Osteomyelitis of lower leg (disorder), Osteomyelitis of multiple sites (disorder), Osteomyelitis of shoulder region (disorder), Osteomyelitis of upper arm (disorder), Unspecified infection of bone of shoulder region, Unspecified infection of bone, ankle and foot, Unspecified infection of bone, forearm, Unspecified infection of bone, hand, Unspecified infection of bone, lower leg, Unspecified infection of bone, upper arm, Unspecified osteomyelitis involving multiple sites, Unspecified osteomyelitis of multiple sites, Unspecified osteomyelitis of multiple sites (disorder), Unspecified osteomyelitis of the ankle and foot, Unspecified osteomyelitis of the ankle and foot (disorder), Unspecified osteomyelitis of the forearm (disorder), Unspecified osteomyelitis of the hand, Unspecified osteomyelitis of the hand (disorder), Unspecified osteomyelitis of the lower leg (disorder), Unspecified osteomyelitis of the shoulder region, Unspecified osteomyelitis of the shoulder region (disorder), Unspecified osteomyelitis of the upper arm (disorder), acute osteomyelitis, acute osteomyelitis involving ankle and foot, acute osteomyelitis involving hand, acute osteomyelitis involving lower leg, acute osteomyelitis involving multiple sites, acute osteomyelitis involving pelvic region and thigh, acute osteomyelitis involving shoulder region, acute osteomyelitis involving upper arm, acute osteomyelitis of ankle and/or foot (disorder), acute osteomyelitis of the ankle and foot, acute osteomyelitis of the ankle and foot (disorder), bone infection NOS, of ankle and foot (disorder), bone infection NOS, of multiple sites (disorder), bone infection NOS, of the forearm (disorder), bone infection NOS, of the hand (disorder), bone infection NOS, of the lower leg (disorder), bone infection NOS, of the shoulder region (disorder), bone infection NOS, of the upper arm (disorder), chronic osteomyelitis, chronic osteomyelitis involving ankle and foot, chronic osteomyelitis involving hand, chronic osteomyelitis involving lower leg, chronic osteomyelitis involving multiple sites, chronic osteomyelitis involving pelvic region and thigh, chronic osteomyelitis involving shoulder region, chronic osteomyelitis involving upper arm, chronic osteomyelitis of ankle and/or foot (disorder), chronic osteomyelitis of the ankle and foot, chronic osteomyelitis of the ankle and foot (disorder), osteomyelitis (disease), osteomyelitis of ankle and foot, osteomyelitis of forearm, osteomyelitis of hand, osteomyelitis of lower leg, osteomyelitis of multiple sites, osteomyelitis of shoulder region, osteomyelitis of upper arm
- Open Targets
- Highest stage of its drugs
- Approval, for 6 of its 31 drugs, from DailyMed and EMA Human Drugs
- Open Targets
Drugs31
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CLINDAMYCIN | CHEMBL1753 | Small molecule | Approval | DailyMed | 3 | 1 | 1 | Drugs and targets |
| CLINDAMYCIN PHOSPHATE | CHEMBL3184512 | Small molecule | Approval | DailyMed | 2 | 0 | 0 | Drugs and targets |
| BESILESOMAB | CHEMBL2108021 | Antibody | Approval | EMA Human Drugs | 1 | 0 | 0 | Drugs and targets |
| ERTAPENEM SODIUM | CHEMBL1232 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| LINEZOLID | CHEMBL126 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| SULESOMAB | CHEMBL2108809 | Antibody | Approval | EMA Human Drugs, at withdrawal | 1 | 0 | 0 | Drugs and targets |
| VANCOMYCIN | CHEMBL262777 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| DALBAVANCIN | CHEMBL3301669 | Protein | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| DAPTOMYCIN | CHEMBL387675 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| CLOXACILLIN | CHEMBL891 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 31
See all 31 drugsTargets0
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
None in this release.
Trials19
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03559530 | Acinetobacter Baumannii-related Osteomyelitis: Clinical and Epidemiological Characterization | 262 | 2021-05-18 | Osteomyelitis | COLISTIN, TIGECYCLINE | Its record names the disease | ClinicalTrials.gov | |
| NCT01922011 | Safety and Efficacy Study of Daptomycin Compared to Active Comparator in Pediatric Participants With Acute Hematogenous Osteomyelitis (AHO) (MK-3009-006) | Phase 3 | 149 | 2017-06-23 | Acute Hematogenous Osteomyelitis | DAPTOMYCIN, NAFCILLIN, VANCOMYCIN | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT02685033 | Study on the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Participants With Osteomyelitis | Phase 2 | 80 | 2019-01-04 | Osteomyelitis | DALBAVANCIN | Its record names the disease | ClinicalTrials.gov |
| NCT00428844 | Study of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by Staphylococci | Phase 2 | 75 | 2011-06-14 | Osteomyelitis | DAPTOMYCIN | Its record names the disease | ClinicalTrials.gov |
| NCT02335905 | Ceftaroline for Treatment of Hematogenously Acquired Staphylococcus Aureus Osteomyelitis in Children | Phase 1/2 | 11 | 2021-11-02 | Hematogenously Acquired Staphylococcus Aureus Osteomyelitis, Bone Infection, Osteomyelitis | CEFTAROLINE FOSAMIL | Its record names the disease | ClinicalTrials.gov |
| NCT03091439 | Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis | Phase 2 | 1 | 2018-09-26 | Osteomyelitis | DALBAVANCIN | Its record names the disease | ClinicalTrials.gov |
| NCT02288234 | Telavancin Observational Use Registry (TOUR) | 1,063 | Hospital Acquired Bacterial Pneumonia, Complicated Skin and Skin Structure Infections, Ventilator Associated Bacterial Pneumonia, Gram Positive Infection | TELAVANCIN | Its record names the disease | ClinicalTrials.gov | ||
| NCT06814899 | Use of Fosfomycin in the Treatment of Bacterial Infections | 300 | Analyze the Medical Records of Patients Admitted At ASST Lecco from 01/04/2020 to 31/12/2023 Treated with Fosfomycin IV | FOSFOMYCIN | Its record names the disease | ClinicalTrials.gov | ||
| NCT07435051 | Prospective, Randomized, Multicenter Clinical Trial of Bisphosphonates Combined With Vancomycin for the Treatment of Cierny-Mader Type I and III Osteomyelitis | Phase 3 | 280 | Osteomyelitis (Refractory) | VANCOMYCIN | Its record names the disease | ClinicalTrials.gov | |
| NCT07575009 | Continuous Antibiotic Infusion In Children | Phase 3 | 150 | Infection | CLOXACILLIN, PENICILLIN G, PIPERACILLIN, TAZOBACTAM, VANCOMYCIN | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 19
See all 19 trialsComparisons in its trials5
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Daptomycin vs Vancomycin or Nafcillin: Number of Participants With 1 or More Adverse Events (AEs) | 34 of 74 | 45 of 72 | 146 | NCT01922011 | Trial comparisons |
| Daptomycin vs Vancomycin or Nafcillin: Number of Participants With 1 or More Serious Adverse Events (SAEs) | 5 of 74 | 4 of 72 | 146 | NCT01922011 | Trial comparisons |
| Daptomycin vs Vancomycin or Nafcillin: serious adverse events | 5 of 74 | 4 of 72 | 146 | NCT01922011 | Trial comparisons |
| Dalbavancin vs Standard of Care: deaths from any cause | 1 of 70 | 0 of 10 | 80 | NCT02685033 | Trial comparisons |
| Dalbavancin vs Standard of Care: serious adverse events | 2 of 70 | 0 of 10 | 80 | NCT02685033 | Trial comparisons |
Papers from its trials10
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005246
GET https://conductscience.org/api/diseases/v1/MONDO_0005246/drugs?page=2